Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. FDA label
Hydrochlorothiazide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Hydrochlorothiazide Tablets 50 mg |
| 2 | ACTIVE_COMPARATOR | Hydrochlorothiazide Tablets 50 mg |
| Name | Type | Description |
|---|---|---|
| Hydrochlorothiazide Tablets 50 mg | DRUG | 50mg, single dose fasting |
| Hydrochlorothiazide Tablets (50 mg | DRUG | 50mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male and/or non-pregnant, non-lactating female a. Women of childbearing potential must have a negative serum (β-HCG) pregnancy test performed within 21 days prior to the start of the study and on the evening prior to each dose administration. I...
Hydrochlorothiazide is a small molecule drug candidate that Viatris Inc. is developing under the name Hydrochlorothiazide Tablets 50 mg. It is being studied in a Phase 1 clinical program. The specific therapeutic indication for this formulation has not been disclosed.
Hydrochlorothiazide targets SLC12A3. It acts as an inhibitor of this target. SLC12A3 is the molecular target listed for the drug, and the compound is classified as a small molecule.
Hydrochlorothiazide is being developed by Viatris Inc., which trades under the ticker symbol VTRS. The company is responsible for the Hydrochlorothiazide Tablets 50 mg program.
Hydrochlorothiazide is in Phase 1 clinical development. It is an investigational drug candidate and has not been approved by the FDA for the studied formulation. The program includes one completed early Phase 1 trial.
Hydrochlorothiazide has been studied in one completed clinical trial, NCT00649324, titled Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg. The trial enrolled 40 healthy volunteers in the United States and was active-controlled and randomized.